Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Revenue

Lineage Cell Therapeutics had revenue of $1.73M in the quarter ending March 31, 2026, with 14.85% growth. This brings the company's revenue in the last twelve months to $14.78M, up 54.64% year-over-year. In the year 2025, Lineage Cell Therapeutics had annual revenue of $14.56M with 53.24% growth.

• Revenue (ttm): $14.78M
• Revenue Growth: +54.64%
• P/S Ratio: 22.60
• Revenue / Employee: $191,935
• Employees: 77
• Market Cap: 326.58M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	14.56M	5.06M	53.24%
Dec 31, 2024	9.50M	554.00K	6.19%
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%
Dec 31, 2019	3.52M	-1.47M	-29.53%
Dec 31, 2018	4.99M	-	-
Dec 31, 2017	-	-	-
Dec 31, 2016	-	-	-
Dec 31, 2015	-	-	-
Dec 31, 2014	1.22M	-3.21M	-72.40%
Dec 31, 2013	4.43M	518.67K	13.25%
Dec 31, 2012	3.92M	-4.87M	-55.45%
Dec 31, 2011	8.79M	1.40M	18.96%
Dec 31, 2010	7.39M	5.46M	283.77%
Dec 31, 2009	1.93M	421.38K	28.02%
Dec 31, 2008	1.50M	457.67K	43.75%
Dec 31, 2007	1.05M	142.92K	15.82%
Dec 31, 2005	903.20K	-	-

Data Source: Fiscal.ai Last updated: May 12, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 14, 2026

Data Sources Report a data error